The estimated Net Worth of John Temperato is at least 752 千$ dollars as of 6 July 2022. Mr Temperato owns over 125,000 units of 9 Meters Biopharma stock worth over 99,927$ and over the last 5 years he sold NMTR stock worth over 0$. In addition, he makes 652,437$ as Pres、 CEO & Director at 9 Meters Biopharma.
Mr has made over 10 trades of the 9 Meters Biopharma stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 125,000 units of NMTR stock worth 28,750$ on 6 July 2022.
The largest trade he's ever made was buying 153,846 units of 9 Meters Biopharma stock on 15 December 2020 worth over 100,000$. On average, Mr trades about 35,942 units every 38 days since 2020. As of 6 July 2022 he still owns at least 1,427,522 units of 9 Meters Biopharma stock.
You can see the complete history of Mr Temperato stock trades at the bottom of the page.
John Temperato is the Pres, CEO & Director at 9 Meters Biopharma.
As the Pres、 CEO & Director of 9 Meters Biopharma, the total compensation of Mr Temperato at 9 Meters Biopharma is 652,437$. There are no executives at 9 Meters Biopharma getting paid more.
Mr Temperato is 56, he's been the Pres、 CEO & Director of 9 Meters Biopharma since . There are 2 older and 1 younger executives at 9 Meters Biopharma. The oldest executive at 9 Meters Biopharma, Inc. is Dr. Patrick H. Griffin, 66, who is the Chief Medical Officer.
John's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 4509 CREEDMOOR ROAD, SUITE 201, RALEIGH, NC, 27612.
Over the last 5 years, insiders at 9 Meters Biopharma have traded over 20,934,964$ worth of 9 Meters Biopharma stock and bought 2,247,050 units worth 1,572,701$ . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra...、Mark A Sirgo、John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of 45,283$. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth 11,011$.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
9 Meters Biopharma executives and other stock owners filed with the SEC include: